Skip Navigation


CIT can broadcast your seminar, conference or meeting live to a world-wide audience over the Internet as a real-time streaming video. The event can be recorded and made available for viewers to watch at their convenience as an on-demand video or a downloadable file. CIT can also broadcast NIH-only or HHS-only content.

Past and Future Therapy for Hepatitis C

Loading video...

345 Views  
   
Air date: Wednesday, November 12, 2014, 3:00:00 PM
Time displayed is Eastern Time, Washington DC Local
Views: Total views: 345, (107 Live, 238 On-demand)
Category: WALS - Wednesday Afternoon Lectures
Runtime: 00:53:03
Description: Wednesday Afternoon Lecture

Annual Astute Clinician Lecture

The Astute Clinician series honors a U.S. clinician-scientist who has observed an unusual clinical occurrence, and by investigating it, has opened an important new avenue of research. Dr. Jay H. Hoofnagle, an expert in liver diseases, has been involved in early evaluation and development of virtually all antiviral agents developed for viral hepatitis including interferon, ribavirin, lamivudine and adefovir dipivoxil.

He has studied Hepatitis C, the most critical area of all liver disease research, for over 30 years. Dr. Hoofnagle will discuss the hepatitis C virus, new insights in how it harms the liver, and new developments of new direct acting antivirals that now promise to cure the majority of patients with this very important liver disease.

For more information go to http://wals.od.nih.gov
Debug: Show Debug
NLM Title: Past and future therapy for hepatitis C / Jay H. Hoofnagle.
Author: Hoofnagle, Jay H.
National Institutes of Health (U.S.),
Publisher:
Abstract: (CIT): Wednesday Afternoon Lecture Annual Astute Clinician Lecture The Astute Clinician series honors a U.S. clinician-scientist who has observed an unusual clinical occurrence, and by investigating it, has opened an important new avenue of research. Dr. Jay H. Hoofnagle, an expert in liver diseases, has been involved in early evaluation and development of virtually all antiviral agents developed for viral hepatitis including interferon, ribavirin, lamivudine and adefovir dipivoxil. He has studied Hepatitis C, the most critical area of all liver disease research, for over 30 years. Dr. Hoofnagle will discuss the hepatitis C virus, new insights in how it harms the liver, and new developments of new direct acting antivirals that now promise to cure the majority of patients with this very important liver disease.
Subjects: Antiviral Agents
Hepacivirus--drug effects
Hepatitis C--drug therapy
Publication Types: Lecture
Webcasts
Download: To download this event, select one of the available bitrates:
[64k]  [150k]  [240k]  [440k]  [740k]  [1040k]  [1240k]  [1440k]  [1840k]    How to download a Videocast
Caption Text: Download Caption File
NLM Classification: WC 536
NLM ID: 101647967
CIT Live ID: 15134
Permanent link: https://videocast.nih.gov/launch.asp?18731